BMRN

54.68

2.44% -1.37

Dopo l'orario di chiusura: 55.00 0.32 +0.59%

Biomarin Pharmaceutical Inc (BMRN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$56.05

Aprire:

$56.32

Volume 24 ore:

2.62M

Relative Volume:

1.01

Capitalizzazione di mercato:

$10.58B

Reddito:

$3.29B

Utile/perdita netta:

$268.74M

Rapporto P/E:

39.90

EPS:

1.3704

Flusso di cassa netto:

$759.12M

1 W Prestazione:

-0.21%

1M Prestazione:

-15.53%

6M Prestazione:

+1.07%

1 anno Prestazione:

+3.27%

Intervallo 1D:

$54.44

$56.53

Intervallo di 1 settimana:

$53.93

$57.59

Portata 52W:

$49.26

$70.98

Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile

Nome

Biomarin Pharmaceutical Inc

Settore

Healthcare (1052)

Industria

Biotechnology (594)

Telefono

(415) 506-6700

Indirizzo

105 DIGITAL DRIVE, NOVATO, CA

Dipendente

3,221

Cinguettio

Prossima data di guadagno

2026-10-26

Ultimi documenti SEC

BMRN's Discussions on Twitter

Compare BMRN vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BMRN Biomarin Pharmaceutical Inc	54.68	10.58B	3.29B	268.74M	759.12M	1.3704
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-10-15	Ripresa	UBS	Buy
2026-10-12	Aggiornamento	Raymond James	Outperform → Strong Buy
2026-08-19	Iniziato	BMO Capital Markets	Outperform
2026-05-19	Iniziato	Citigroup	Buy
2026-05-11	Ripresa	Goldman	Neutral
2026-04-27	Ripresa	Morgan Stanley	Overweight
2026-01-28	Ripresa	Barclays	Overweight
2026-01-20	Aggiornamento	Canaccord Genuity	Hold → Buy
2025-12-03	Downgrade	Leerink Partners	Outperform → Market Perform
2025-11-06	Downgrade	Stifel	Buy → Hold
2025-09-08	Iniziato	H.C. Wainwright	Neutral
2025-09-03	Iniziato	Raymond James	Outperform
2025-07-03	Ripresa	Morgan Stanley	Overweight
2025-02-24	Aggiornamento	Oppenheimer	Perform → Outperform
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-10-30	Downgrade	William Blair	Outperform → Mkt Perform
2024-10-10	Ripresa	Raymond James	Outperform
2024-08-20	Aggiornamento	Bernstein	Mkt Perform → Outperform
2024-05-17	Downgrade	Robert W. Baird	Outperform → Neutral
2024-05-14	Iniziato	Evercore ISI	Outperform
2023-11-15	Iniziato	Wells Fargo	Overweight
2023-10-23	Aggiornamento	Bernstein	Underperform → Mkt Perform
2023-09-28	Iniziato	Raymond James	Mkt Perform
2023-09-18	Iniziato	UBS	Buy
2023-07-27	Iniziato	Scotiabank	Sector Perform
2023-07-05	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-06-14	Ripresa	Credit Suisse	Outperform
2023-03-21	Iniziato	Bernstein	Underperform
2023-02-22	Downgrade	Oppenheimer	Outperform → Perform
2023-02-21	Iniziato	Citigroup	Neutral
2023-01-30	Iniziato	BMO Capital Markets	Market Perform
2023-01-18	Iniziato	Canaccord Genuity	Hold
2022-10-31	Aggiornamento	Oppenheimer	Perform → Outperform
2022-07-13	Iniziato	Cantor Fitzgerald	Overweight
2022-06-13	Ripresa	Wedbush	Neutral
2022-04-25	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-11-22	Aggiornamento	William Blair	Mkt Perform → Outperform
2021-10-07	Ripresa	Jefferies	Buy
2021-09-09	Aggiornamento	Stifel	Hold → Buy
2021-06-04	Ripresa	Robert W. Baird	Outperform
2021-04-26	Ripresa	Credit Suisse	Outperform
2021-03-04	Ripresa	Guggenheim	Buy
2021-03-01	Aggiornamento	Evercore ISI	In-line → Outperform
2020-08-20	Downgrade	Citigroup	Buy → Neutral
2020-08-20	Downgrade	William Blair	Outperform → Mkt Perform
2020-08-19	Downgrade	Evercore ISI	Outperform → In-line
2020-08-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2020-08-19	Downgrade	Stifel	Buy → Hold
2020-07-08	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2020-07-06	Reiterato	Citigroup	Buy
2020-01-28	Iniziato	BMO Capital Markets	Market Perform
2020-01-27	Iniziato	BMO Capital Markets	Market Perform
2020-01-24	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2019-11-27	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-12	Iniziato	SunTrust	Buy
2019-10-17	Ripresa	BofA/Merrill	Buy
2019-05-23	Ripresa	Citigroup	Buy
2019-04-09	Ripresa	Raymond James	Outperform
2019-01-02	Downgrade	Raymond James	Outperform → Mkt Perform
2018-12-14	Iniziato	Wolfe Research	Outperform
2018-10-01	Iniziato	Cantor Fitzgerald	Overweight
2018-08-07	Reiterato	Stifel	Buy
2018-08-03	Reiterato	Stifel	Buy

Mostra tutto

Biomarin Pharmaceutical Inc Borsa (BMRN) Ultime notizie

Oct 12, 2026

Raymond James upgrades BioMarin stock to strong buy on valuation - Investing.com

Oct 12, 2026

Why is BioMarin Pharmaceutical stock gaining today? By Investing.com - Investing.com Canada

Oct 12, 2026

Raymond James upgrades BioMarin stock to strong buy on valuation By Investing.com - Investing.com South Africa

Oct 12, 2026

Oct 10, 2026

Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 10, 2026

Oct 09, 2026

RBC Capital Keeps Their Hold Rating on BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 09, 2026

BioMarin to present data on achondroplasia treatment at ASBMR - Investing.com

Oct 09, 2026

New imaging data examine a growth drug's effect on a skull area linked to serious complications in children. - Stock Titan

Oct 09, 2026

Oct 08, 2026

BioMarin Pharmaceutical (BMRN), What Is Behind The Latest Attention? - Yahoo Finance

Oct 08, 2026

Analysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail

Oct 08, 2026